Document is current
Any future updates will be listed below
-
Authors
Das, Shreyasee
Goossens, Julie
Jacobs, Dirk
Dewit, Nele
Pijnenburg, Yolande A. L.
In ‘t Veld, Sjors G. J. G.
Teunissen, Charlotte E.
Vanmechelen, Eugeen
-
Funding
Funding for this research was provided by:
H2020 European Institute of Innovation and Technology (860197, 860197, 18HLT09, 860197, 860197)
- License Information
-
More Information
Article History
Received: 12 November 2022
Accepted: 14 March 2023
First Online: 24 March 2023
Declarations
:
: All animal experiments were performed in accordance with the ARRIVE guidelines, following good laboratory practices and ethical regulations. All clinical CSF samples were procured as a part of the Amsterdam Dementia Cohort Biobank agreement.
: Not applicable.
: S.D., J.G., and D.J. are employees of ADx NeuroSciences, Gent, Belgium. S.D. is also enrolled as a Ph.D. candidate at the Amsterdam University Medical Centre, Amsterdam, Netherlands. E.V.M. is the co-founder of ADx NeuroSciences. C.T. has a collaboration contract with ADx NeuroSciences, Quanterix, and Eli Lilly and has performed contract research or received grants from AC-Immune, Axon Neurosciences, Bioconnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Grifols, Novo Nordisk, PeopleBio, Roche, Toyama, and Vivoryon. She serves on editorial boards of Medidact Neurologie/Springer, Alzheimer Research and Therapy, Neurology: Neuroimmunology & Neuroinflammation, and is the editor of a Neuromethods book Springer. All the other authors declare no competing interests.
